COVID-19 Evidence Network to support Decision-making (COVID-END)

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:240 publications

Grant number: Unknown

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $750,000
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    N/A

  • Research Location

    Canada
  • Lead Research Institution

    McMaster University
  • Research Priority Alignment

    N/A
  • Research Category

    Policies for public health, disease control & community resilience

  • Research Subcategory

    Policy research and interventions

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The science about how to prevent and manage COVID-19 and its spill-over effects on society is changing rapidly. Summaries of the best available science (which we call evidence syntheses) are the best place to turn when making decisions about public-health measures (e.g., wearing masks), clinical management (e.g., prescribing drugs), health-system arrangements (e.g., making the most of virtual doctor visits), and economic and social responses (e.g., adjusting schools and workplaces). COVID-END will bring together: 1) 25+ Canadian evidence-synthesis teams; 2) leaders of key Canadian initiatives that support the use of science by citizens, service providers and policymakers; 3) diverse citizen partners from across Canada; 4) Canadian professional bodies; and 5) policymakers and leaders from Canadian governments and health authorities. COVID-END will: 1)prepare and update evidence syntheses at the request of Canadian decision-makers in timelines ranging from 4 hours to 10 days; 2)maintain an inventory of the best evidence syntheses for COVID-19 decisions to ensure that Canadian decision-makers have available at all times the most updated summarized science; 3)work with Canadian decision-makers to ensure that their most urgent questions are prioritized and responded to by the most appropriate team in a timely way and that these decision-makers have the capacity to find and use the available science in their decision-making; 4)keep alert to emerging issues where evidence syntheses may be needed in the future; and 5)work with Canadian and global partners to reduce duplication and enhance coordination in the evidence response to COVID-19. COVID-END will undertake (or co-create) its work in close partnership with citizens and with the decision-makers who pose questions and whose existing processes we need to intersect with. COVID-END will disseminate and support the use of its work both directly and through many existing initiatives.

Publicationslinked via Europe PMC

Dysregulated Alternative Splicing in Breast Cancer Subtypes of RIF1 and Other Transcripts.

Development and Validation of the Intimate Partner Violence Workplace Disruptions Assessment (IPV-WDA).

Elucidating directed neural dynamics of scene construction across memory and imagination

Implementing a Novel Resident-Led Peer Support Program for Emergency Medicine Resident Physicians.

Cross-Activity Analysis of CRISPR/Cas9 Editing in Gene Families of <i>Solanum lycopersicum</i> Detected by Long-Read Sequencing.

Creating health systems citizens: enhanced professional identity formation through a para-curricular distinction track in health systems transformation and leadership.

A Comparison of Clinical Diagnostic Classification Criteria Used in Longitudinal Cohort Studies of the Alzheimer's Disease Continuum: A Systematic Review.

Identification and Characterization of a Rare Exon 22 Duplication in <i>CFTR</i> in Two Families.

Structural Rearrangement in Cyclic Cu(II) Pyridyltriazole Complexes: Oxidation of Dabco to Oxalate and CO<sub>2</sub> Conversion to Carbonate.